CA
TYRA icon

CoreCap Advisors’s Tyra Biosciences TYRA Stock Holding History

CoreCap Advisors’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16
Closed -$149 – 3241
2025
Q1 		$149 Hold
16
– – ﹤0.01% 3028
2024
Q4 		$222 Buy
+16
New +$290 ﹤0.01% 2714

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
APMC
Alta Partners Management Company Jackson, Wyoming $151M AUM 296.21% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $127M AUM 217.49% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

CoreCap Advisors's TYRA Position: Q2 2025 in Review

CoreCap Advisors sold out of Tyra Biosciences (TYRA) in Q2 2025, closing a stake of 16 shares — an estimated $149 sold.

CoreCap Advisors first reported a position in TYRA in Q4 2024 and held it in 2 quarters. The position peaked at $222 in Q4 2024. 121 funds tracked by Wall St. Rank hold TYRA as of Q2 2025.

  • CoreCap Advisors reported no remaining Tyra Biosciences position as of Q2 2025 after selling out during the quarter.
  • CoreCap Advisors sold 16 Tyra Biosciences shares in Q2 2025, an estimated $149.
  • CoreCap Advisors first reported a position in Tyra Biosciences in Q4 2024 and held it in 2 quarters.
  • CoreCap Advisors's Tyra Biosciences position peaked at $222 in Q4 2024.
  • 121 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.